Nano-X Imaging Stock (NASDAQ:NNOX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$7.36

52W Range

$5.26 - $14.28

50D Avg

$6.28

200D Avg

$7.73

Market Cap

$427.63M

Avg Vol (3M)

$1.95M

Beta

2.00

Div Yield

-

NNOX Company Profile


Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company develops a prototype of the Nanox.ARC, a medical imaging system incorporating its digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that would allow for the delivery of medical screening as a service. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company was founded in 2011 and is headquartered in Neve Ilan, Israel.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

164

IPO Date

Aug 21, 2020

Website

NNOX Performance


NNOX Financial Summary


Dec 23Dec 22Dec 21
Revenue$9.90M$8.58M$1.30M
Operating Income$-61.08M$-109.71M$-61.56M
Net Income$-60.78M$-105.24M$-61.80M
EBITDA$-49.27M$-37.19M$-61.56M
Basic EPS$-1.08$-2.01$-1.28
Diluted EPS$-1.08$-2.01$-1.28

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 21, 24 | 11:47 AM
Q2 24Aug 20, 24 | 11:36 AM
Q1 24May 28, 24 | 12:00 AM

Peer Comparison


TickerCompany
IARTIntegra LifeSciences Holdings Corporation
PACBPacific Biosciences of California, Inc.
MASS908 Devices Inc.
ABTAbbott Laboratories
SYKStryker Corporation
EWEdwards Lifesciences Corporation
AXNXAxonics, Inc.
MDTMedtronic plc
DXCMDexCom, Inc.
MGRMMonogram Orthopaedics, Inc.
NVCRNovoCure Limited
HYPRHyperfine, Inc.
ALGNAlign Technology, Inc.